EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> PolyProx Therapeutics, a University of Cambridge spinout, raised £3.4 million ($4.4 million) to work on drugs that engage cellular degradation machinery to stop tumor growth. Release

> 4D Pharma completed an early part of its phase 1/2 Keytruda combination trial without seeing dose-limiting toxicities. Statement 

> Freeline Therapeutics struck a multi-year agreement with Brammer Bio to secure access to gene therapy production capacity in the U.S. The capacity will support potential commercial demand for hemophilia B gene therapy FLT180a. Release

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Baylor College of Medicine presented data on its Cell Medica-partnered GD2-CAR NKT cells. One of two patients treated with the lowest dose of the drug experienced “extensive tumor regression at four weeks.” Statement

> Amal Therapeutics teamed up with Boehringer Ingelheim to test its ATP128 in combination with anti-PD-1 antibody BI754091. Release

> Numab offloaded the Chinese rights to a trispecific antibody-based molecule targeting PD-L1, 4-1BB and human serum albumin to CStone Pharmaceuticals. Statement 

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.